World Journal of
Pharmaceutical and Life Sciences

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical and Life Sciences
An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)
World Journal of Pharmaceutical and Life Sciences (WJPLS) has indexed with various reputed international bodies like : Google Scholar, Index Copernicus, Indian Science Publications, SOCOLAR, China, Cosmos Impact Factor, Research Bible, Fuchu, Tokyo. JAPAN, Scientific Indexing Services (SIS), Jour Informatics (Under Process), UDLedge Science Citation Index, Global Impact Factor (In Process), International Impact Factor Services, International Scientific Indexing, UAE, International Society for Research Activity (ISRA) Journal Impact Factor (JIF), Science Library Index, Dubai, United Arab Emirates, International Innovative Journal Impact Factor (IIJIF), Scientific Journal Impact Factor (SJIF), Eurasian Scientific Journal Index (ESJI), Indian citation Index (ICI), IFSIJ Measure of Journal Quality, International Scientific Indexing, UAE (ISI), Web of Science Group (Under Process), Directory of Research Journals Indexing, 

Abstract

PREVENTIVE THERAPIES USING SODIUM CHANNEL BLOCKERS FOR CONGENITAL LONG QT SYNDROME

Dr. Toshimasa Nakada*

ABSTRACT

Preventive therapy for pediatric patients with congenital long QT syndrome (LQTS) without severe cardiac symptoms has not been established. The objective of this study was to clarify the outcomes of pediatric patients with LQTS who were diagnosed without severe cardiac symptoms and who received preventive therapy using sodium channel blockers (SB). This retrospective study included data from seven patients with LQTS who received preventive therapy using SB. The outcomes of those patients and changes of corrected QT intervals (QTc) before and after treatment were studied. Three patients received mexiletine alone, and four patients received combination therapy with propranolol and SB. The median follow-up period from the initial treatment to the last follow-up was one year and one month (range: 6 months to 15 years and 6 months). No cardiac events developed after treatment. The QTc values after therapy were significantly shorter than those before: median QTc 454 (range: 396–475) vs. 485 (range: 470–527) ms, P < 0.05.

[Full Text Article]

BEST PAPER AWARDS

World Journal of Pharmaceutical and life sciences Will give best paper award in every issue in the from of money along with certificate to promote research .

Best Article of current issue

Download Article : Click here